ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
0.5790
+0.0540 (10.29%)
At close: Jun 6, 2025, 4:00 PM
0.5750
-0.0040 (-0.69%)
After-hours: Jun 6, 2025, 7:31 PM EDT
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
80
Market Cap
30.94M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ALXO News
- 8 days ago - ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewsWire
- 18 days ago - ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - GlobeNewsWire
- 25 days ago - ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - GlobeNewsWire
- 4 weeks ago - ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - GlobeNewsWire
- 6 weeks ago - ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewsWire
- 6 weeks ago - ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints - GlobeNewsWire
- 3 months ago - ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire